1.085USD-0.46%Mkt Cap: 12.55M USDP/E: —Last update: 2026-05-26
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expr…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap12.55M USD
Enterprise Value-4.37M USD
Revenue (TTM)—
Gross Profit-4.62M USD
Net Income (TTM)-8.70M USD
Revenue/Share—
Last Price1.085 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees6
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.27
PEG—
EV/EBITDA0.38
EV/Revenue—
P/S—
P/B0.77
EPS (TTM)-1.38
EPS (Forward)-0.86
52W Range
0.81308% of range4.190
52W High4.190 USD
52W Low0.8130 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-43.17%
ROA-40.48%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.98M USD
CapEx (TTM)12.00K USD
FCF Margin—
FCF Yield-57.82%
Net Debt-17.03M USD
Net Debt/EBITDA1.48
Balance Sheet
Debt/Equity—
Current Ratio18.32
Quick Ratio17.93
Book Value/Sh1.417 USD
Cash/Share1.466 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJan 15, 2020
Splits
Last Split1:9
Split DateJul 5, 2024
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)14.00 USD
Target Range14.00 USD – 14.00 USD
# Analysts1
Ownership
Shares Out.11.62M
Float11.55M
Insiders6.00%
Institutions10.82%
Short Interest
Short Ratio2.9d
Short % Float4.06%
Short % Out.4.04%
Shares Short469.57K
Short (prev mo.)571.89K
Technical
SMA 501.201 (-9.7%)
SMA 2001.496 (-27.5%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)139.33K
Avg Vol (10d)138.86K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—